Immunome reports Q2 2024 net loss of $36.1M; cash $278.4M, runway into 2026

Immunome Inc.

2024-Q2 EPS reported -$2.97 revenue$3,393,000

Cash, equivalents and marketable securities totaled $278.4M; expected runway into 2026.
Net loss of $36.1M for Q2 2024; R&D expense $29.1M, G&A $7.0M.
Phase 3 RINGSIDE Part B (AL102) for desmoid tumors fully enrolled; topline data expected H2 2025.
IND submissions for IM-1021 and IM-3050 anticipated in Q1 2025.
Business development transactions with Atreca, Nectin Therapeutics, Bluefin, OncoResponse expanding ADC toolbox.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.